

Pangea Biomed

- **Investment Rational**

Pangea Biomed developed a unique platform for pan-cancer prediction of response to targeted and immunotherapies, which can significantly increase the percentage of patients benefiting from precision oncology. We have established collaborations with pharma and diagnostics companies, as well as with the US National Cancer Institute. The platform supports diagnostics and drug development, with a market potential of more than \$60B.

- **Business Strategy**

Pangea's short-term strategy focuses on collaborations with bio-pharma companies. We help our partners optimize their preclinical and clinical programs through the use of our accurate transcriptomic biomarkers: optimizing clinical trial design, expanding target indications and finding optimal combination therapies. In the longer term, our focus is on actionable clinical reports, identifying viable treatment options for a majority of patients.

- **Core Technology**

ENLIGHT is a computational platform that identifies and utilizes clinically relevant genetic interactions, and can predict the response to drugs for which little or no outcome data is available for training. ENLIGHT achieves high precision in diverse indications, predicting response to a variety of targeted and immunotherapies, and can markedly enhance the success of clinical trials by excluding non-responders.

- **Product Profile/Pipeline**

Pangea's ENLIGHT platform supports multiple applications for drug discovery, development and treatment guidance. The current focus on pharma applications has market potential measured in billions, while the clinical applications open up even larger future markets. In addition to signed pharma deals, we already have a collaboration with one of the largest oncology diagnostics players, turning our biomarkers into approved tests.

- **What's Next?**

We are extending our offering by using the latest sequencing and AI technologies to derive better predictions from novel molecular pathology modalities. In parallel, we are forming a US subsidiary and starting large prospective trials in Israel and the US, the latter in collaboration with the NCI. Pangea is currently in the process of raising its Series A financing.